Champions Oncology, Inc. provided revenue guidance for the fiscal year 2023. For the period, the company expecting its total revenue growth for fiscal 2023 to be in the 10% to 15% range, down from the approximate 20% range provided at the beginning of the year.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.57 USD | +1.11% | -3.08% | -18.68% |
15/03 | Tranche Update on Champions Oncology, Inc.'s Equity Buyback Plan announced on April 5, 2023. | CI |
13/03 | Craig-Hallum Downgrades Champions Oncology to Hold From Buy | MT |
1st Jan change | Capi. | |
---|---|---|
-18.68% | 62.12M | |
+43.29% | 58.71B | |
-2.64% | 41.31B | |
+36.67% | 39.2B | |
-10.22% | 27.4B | |
+12.05% | 26.55B | |
-22.50% | 18.98B | |
+0.99% | 12.51B | |
+26.69% | 12.08B | |
+22.30% | 11.94B |
- Stock Market
- Equities
- CSBR Stock
- News Champions Oncology, Inc.
- Champions Oncology, Inc. Provides Revenue Guidance for the Fiscal Year 2023